Pardo M, Marriott E, Moliner M C, Quiroga J A, Carreño V
Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain.
Drug Saf. 1995 Nov;13(5):304-16. doi: 10.2165/00002018-199513050-00004.
The high worldwide prevalence of chronic viral hepatitis, as well as its progressive course, have led to the performance of multiple clinical studies. The natural history of the disease is different depending on the infecting virus; thus, the evolution to liver cirrhosis and/or hepatocellular carcinoma for the hepatitis B, C and delta (D) viruses in chronic hepatitis is 15, 20 and 75%, respectively. Different therapeutic agents have been used in attempts to modify the natural course of these diseases, interferon-alpha (IFN alpha) having proved to be the most effective. In 30 to 50% of patients, treatment with IFN alpha has achieved inhibition of viral replication, as well as normalisation of aminotransferase levels. Moreover, in a majority of patients, histological improvement is observed, principally in piece-meal necrosis and portal inflammation. The dosage currently recommended for treatment of chronic hepatitis B is 30 to 35MU weekly for a minimum of 4 months; when there is a co-existing delta virus infection, the total dosage employed should be greater. For hepatitis C, the minimum effective dosage is 9MU weekly, and a treatment duration of 12 months is recommended. The administration of IFN alpha produces a series of dose-dependent adverse effects, which are reversible on suspension of the medication. The most frequent of these adverse reactions is the 'flu-like' syndrome, which is self-limited and generally well tolerated. Secondary haematological alterations (leucopenia and thrombocytopenia) are the most frequent cause of reduction in dosage or suspension of treatment, although the latter is not normally necessary. The proportion of patients requiring dosage modification or suspension of treatment fluctuates between 5 and 15%. Taking the evolution of chronic hepatitis into account, there can be no doubt that all patients with this disease should be offered treatment. At present, the drug of choice is IFN alpha, as it slows disease progression and it is generally well tolerated.
慢性病毒性肝炎在全球范围内的高患病率及其进展过程,促使了多项临床研究的开展。该疾病的自然史因感染病毒的不同而有所差异;因此,慢性肝炎中乙型、丙型和丁型病毒发展为肝硬化和/或肝细胞癌的比例分别为15%、20%和75%。人们尝试使用不同的治疗药物来改变这些疾病的自然病程,其中α干扰素(IFNα)已被证明是最有效的。在30%至50%的患者中,使用α干扰素治疗可抑制病毒复制,并使转氨酶水平恢复正常。此外,大多数患者的组织学也有改善,主要表现为碎片状坏死和门脉炎症减轻。目前推荐用于治疗慢性乙型肝炎的剂量是每周30至35MU,至少持续4个月;如果同时存在丁型病毒感染,使用的总剂量应更大。对于丙型肝炎,最小有效剂量是每周9MU,建议治疗持续12个月。α干扰素的使用会产生一系列剂量依赖性不良反应,停药后这些反应可逆转。其中最常见的不良反应是“流感样”综合征,该综合征具有自限性,通常耐受性良好。继发性血液学改变(白细胞减少和血小板减少)是最常见的导致剂量减少或停药的原因,不过通常无需停药。需要调整剂量或停药的患者比例在5%至15%之间波动。考虑到慢性肝炎的发展情况,毫无疑问所有患有这种疾病的患者都应该接受治疗。目前,首选药物是α干扰素,因为它能减缓疾病进展,而且通常耐受性良好。